Professional Marketing briefs
Eisai received a DDMAC warning letter for a Dacogen patient-profile card, a sales aid used when detailing physicians. DDMAC said the card was misleading, because it minimizes risks, overstates efficacy and omits material facts.
Celgene is poised to bring Istodax to market after acquiring the firm that oversaw development, Gloucester Pharmaceuticals. An early 2010 launch is planned for the lymphoma drug.
A recommendation issued by the New Jersey Division of Consumer Affairs calls for a new Board of Medical Examiners rule requiring that 25% of licensed physicians' CME be obtained in evidence-based educational programs or academic detailing.